Cell therapy developer Autolus has a lead program under FDA review for a type of blood cancer and in clinical development for other indications. As the company looks ahead to a potential product ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you. Good morning ...

JERUSALEM, Israel, and MAINZ, Germany, September 7, 2022 —BioNTech SE (BNTX) (Nasdaq: BNTX) announced today that Prof. Ugur Sahin, CEO and Co-founder of BioNTech (NTGN), visited Israel to meet with ...

U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. BERLIN (AP) — German vaccine maker BioNTech, ...

BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a late-stage oncology bispecific antibody, the drugmaker announced Wednesday. The ...